- 25371 Commercentre Dr, Lake Forest, CA 92630
- Patients Results
Comprehensive DNA and RNA profiling for solid tumors and hematologic malignancies, including liquid biopsy that integrates cell free DNA and cell free RNA to reveal clinically meaningful tumor signatures.
Genomic Testing Cooperative is a cooperative model clinical laboratory designed to expand access to advanced cancer genomics without compromising clinical rigor. We combine next generation sequencing with informatics and AI driven interpretation to translate complex molecular data into reports that are practical for real world decision making, whether the case is a solid tumor, a hematologic malignancy, or a liquid biopsy scenario where tissue is limited.
Dr. Albitar is a board certified pathologist with deep expertise across hematopathology and molecular diagnostics, with extensive executive leadership experience in large scale laboratory environments and a long track record in scientific publishing and innovation.
Our testing is focused on comprehensive profiling of DNA and RNA in hematologic neoplasms and solid tumors, embracing the latest sequencing technology and informatics tools; providing better insights into the patient’s tumor signature. Our RNA sequencing capabilities go beyond just the detection of fusions and include alternative splicing, gene expression and prediction. Our RNA profiling can be used to compliment flow cytometry and immunohistochemistry (IHC) testing. GTC’s capabilities include liquid biopsy testing that give physicians testing options when tissue or bone marrow isn’t available. The informatics tools we use utilize artificial intelligence with sophisticated algorithms to interpret complex data sets, these informatics tools are unmatched anywhere on the market today.
GTC was founded in 2018 by Maher Albitar, MD who has held senior roles at numerous diagnostic laboratories and was a tenured professor at MD Anderson Cancer Center. He has committed his life to helping cancer patients by advancing cancer diagnostics and democratizing testing. Dr. Albitar founded GTC because he had a vision to revolutionize diagnostics and scientific discovery by improving access to comprehensive genomic profiling with next generation sequencing. He believes every cancer patient should have access to comprehensive genomic profiling. Dr. Albitar is regularly published in the top medical journals in oncology and has over 300 publications and authored over 50 patents.
Our approach is built around integrated DNA and RNA profiling and a streamlined menu that covers both heme and solid tumors, so teams can get comprehensive answers up front. The goal is speed with substance: actionable insights delivered in a clinically relevant format, backed by a cooperative mindset that prioritizes collaboration, operational efficiency, and consistent quality.
We offer advanced genomic profiling for both solid and hematologic cancers to communities everywhere at an affordable price.
GTC utilizes a cooperative business model to help physicians treat patients locally with the most advanced precision medicine made possible by advanced diagnostic information.
We embrace disruptive technology and deep learning to create scalable efficiencies, incomparable precision, and a more personalized approach to patient care.
We are committed to driving the field of oncology forward by enabling more patients to contribute their unique cancer experience to the growing body of cancer genomics data.
We are committed to fulfilling precision medicine’s promise of individualized care for everyone by empowering physicians to formulate treatments that best suit each patient’s unique genetic profile.
Our aim is to offer you:
Machine / Deep Learning (AI) is the center of our analysis that provides:
Genomics Testing Cooperative is established.
GTC tests receive coverage decision from Medicare (Palmetto GBA) for all its tests including liquid biopsies
GTC partners with John Theuer Cancer Center/RCCA to open genomics laboratory
GTC partners with Hackensack Meridian Health to open genomics laboratory
Anthology Diagnostics opens in collaboration with Hackensack Meridian Health
New lab at John Theurer Cancer Center
GTC’s testing is well validated with our menu receiving numerous accreditations including Medicare approval, NY State and CE Mark.
GTC Moved to own premises
CorePath Laboratories selects Genomic Testing Cooperative as a long-term partner for NGS diagnostics for hematologic neoplasms and solid tumors.
GTC receives license to offer testing to patients in the United Kingdom
Partners with GTC to open a co-op lab that services the North Eastern US
GTC receives the ACG award for its growth and commitment to innovation.
AdentHealth partners with GTC to open a Co-Op lab in Orlando, FL
